Metamark Genetics said today it inked a collaborative deal to act as the exclusive worldwide sales agent for Hologic‘s (NSDQ:HOLX) Progensa PCA3 assay, designed to test for prostate cancer. The Progensa PCA3 is the 1st urine-based molecular test of its kind, according to Metamark. The test is designed to quantify cancer-specific overexpression of prostate cancer antigen […]
Here’s a roundup of recent clinical trial and scientific study news:
Metamark Genetics Inc. entered into a global licensing agreement with HistoRx Inc. for its Aqua technology.
The Naples, Fla.-based firm, which has operations in Cambridge, Mass., has been developing its diagnostic assays for cancer analysis using the HistoRx protein biomarker diagnostic for several years, according to the company.
Metamark Genetics Inc. completed its Series B round to expand the company’s R&D operation and clinical testing facilities.
The Naples, Fla.-based firm, which has operations in Cambridge, Mass., raised $22 million from three investors in a $42 million equity offering, according to an SEC filing.